RITUXAN—continuing to steer the way with powerful data
2010—RITUXAN is approved for patients with chronic lymphocytic leukemia (CLL) with proven progression-free survival (PFS)
In February 2010, RITUXAN received approval for the treatment of patients with previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide.
Learn more about RITUXAN's efficacy in first-line and previously treated CLL in combination with FC.
2006—RITUXAN is approved for previously untreated follicular Non-Hodgkin's Lymphoma (NHL) with proven PFS
In September 2006, RITUXAN received approval for previously untreated follicular, CD20+, B-cell NHL in combination with CVP chemotherapy.
Learn more about RITUXAN's efficacy in previously untreated follicular Non-Hodgkin's Lymphoma (NHL) in combination with CVP.
2006—RITUXAN is approved for low-grade Non-Hodgkin's Lymphoma (NHL) with proven risk reduction (risk of progression, relapse or death)
In September 2006, RITUXAN also received approval for the treatment of non-progressing (including stable disease), low-grade, CD20+ B-cell NHL, as a single agent, after first-line CVP chemotherapy.
Learn more about RITUXAN's efficacy in non-progressing low-grade Non-Hodgkin's Lymphoma (NHL) after CVP.
2006—RITUXAN is approved for previously untreated DLBCL with proven overall survival
In February of 2006, RITUXAN was approved for previously untreated DLBCL in combination with CHOP or other anthracycline-based chemotherapy regimens.
Learn more about RITUXAN's efficacy in previously untreated DLBCL with CHOP.
2001—RITUXAN is approved for retreatment, bulky disease and weekly x8 with proven durable responses
In 2001, RITUXAN received approval in the United States with a package insert expanded to include information on the administration of RITUXAN treatment weekly for 8 doses, for the treatment of bulky disease, and for 4 weekly doses as retreatment.
Learn more about RITUXAN's efficacy in relapsed or refractory, low-grade or follicular NHL.
1997—RITUXAN is the first monoclonal antibody therapy approved in the US for cancer (relapsed or refractory, low-grade or follicular NHL)
In 1997, RITUXAN became the first monoclonal antibody approved for the treatment of cancer in the United States, when approval was obtained for the treatment of relapsed or refractory low-grade or follicular, CD20+, B-cell non-Hodgkin's lymphoma. Since the discovery and development of RITUXAN, it has become the focus of extensive clinical research throughout the world.
Since its approval, interest in RITUXAN has continued to grow, with numerous clinical trial research protocols either completed or planned, or in progress investigating RITUXAN in patients with low-grade, intermediate, and high-grade lymphoma. The number of research abstracts and clinical trial reports in the literature has risen sharply over the years, and continues to grown.
Learn more about the weekly x4 trial.
INDICATIONS AND IMPORTANT SAFETY INFORMATION
RITUXAN® (Rituximab) is indicated for the treatment of patients with:
- Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC)
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Weekly ×4
- Weekly ×8
- Bulky disease
- Retreatment
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
RITUXAN is not recommended for use in patients with severe, active infections.
WARNING: FATAL INFUSION REACTIONS, TUMOR LYSIS SYNDROME (TLS), SEVERE MUCOCUTANEOUS REACTIONS, and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
Infusion Reactions: RITUXAN administration can result in serious, including fatal, infusion reactions. Deaths within 24 hours of RITUXAN infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Carefully monitor patients during infusions. Discontinue RITUXAN infusion and provide medical treatment for Grade 3 or 4 infusion reactions.
Tumor Lysis Syndrome (TLS): Acute renal failure requiring dialysis with instances of fatal outcome can occur in the setting of TLS following treatment of non-Hodgkin’s lymphoma (NHL) with RITUXAN monotherapy.
Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving RITUXAN.
Progressive Multifocal Leukoencephalopathy (PML): JC virus infection resulting in PML and death can occur in patients receiving RITUXAN.
RITUXAN has also been associated with other serious and/or fatal adverse reactions. These include hepatitis B reactivation with fulminant hepatitis, other infections, cardiovascular events, renal toxicity, and bowel obstruction and perforation.
The most common adverse reactions of RITUXAN (incidence ≥25%) observed in clinical trials of patients with NHL were infusion reactions, fever, lymphopenia, chills, infection, and asthenia. The incidence of infusion reactions was highest during the first infusion (77%) and decreased with each subsequent infusion. These infusion reactions typically resolved with slowing or interruption of the infusion and with supportive care. The most frequent Grade 3 or 4 adverse reactions observed in NHL were cytopenias.
The most common adverse reactions of RITUXAN (incidence ≥25%) observed in clinical trials of patients with CLL were infusion reactions and neutropenia. Infusion-related adverse reactions occurring during or within 24 hours of the start of infusion included nausea, pyrexia, chills, hypotension, vomiting, and dyspnea. Most patients treated with R-FC experienced at least one Grade 3 or 4 adverse reaction. The Grade 3 or 4 adverse reactions observed more frequently with R-FC compared with FC alone were neutropenia, leukopenia, febrile neutropenia, thrombocytopenia, infusion reactions, pancytopenia, hypotension, and hepatitis B.
In clinical trials, CLL patients 70 years of age or older who received R-FC had more Grade 3 and 4 adverse reactions compared with younger CLL patients who received the same treatment.
For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.
Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.
References
- ClinicalTrials.gov. http://clinicaltrials.gov. Accessed January 14, 2010.
- Data on file, Genentech, Inc.
